Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook
January 31, 2023 16:01 ET
|
Taysha Gene Therapies, Inc.
Type B end-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) provided additional clarity for TSHA-120 for the treatment of giant axonal neuropathy (GAN) ultra-rare disease program - FDA...
Taysha Gene Therapies Announces Executive Leadership Changes
December 16, 2022 18:19 ET
|
Taysha Gene Therapies, Inc.
Chair of the Board of Directors, Sean P. Nolan, appointed Chief Executive Officer Board Director, Sukumar Nagendran, M.D., appointed President and Head of R&D DALLAS, Dec. 16, 2022 (GLOBE...
Taysha Gene Therapies to Participate in JMP Securities Hematology and Oncology Summit
November 29, 2022 16:01 ET
|
Taysha Gene Therapies, Inc.
DALLAS, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 08, 2022 07:00 ET
|
Taysha Gene Therapies, Inc.
$50 million strategic investment from Astellas Pharma to support development of TSHA-120 in giant axonal neuropathy (GAN) and TSHA-102 in Rett syndrome Proceeds from follow-on offering along with...
Taysha Gene Therapies to Release Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 8
November 02, 2022 07:00 ET
|
Taysha Gene Therapies, Inc.
DALLAS, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
Taysha Announces Pricing of Public Offering of Common Stock
October 26, 2022 19:54 ET
|
Taysha Gene Therapies, Inc.
DALLAS, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing...
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock
October 25, 2022 16:01 ET
|
Taysha Gene Therapies, Inc.
DALLAS, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
Taysha Gene Therapies to Host Conference Call to Discuss Astellas Pharma’s Strategic Investment to Support the Development of Taysha’s AAV-based Gene Therapy Programs
October 24, 2022 19:35 ET
|
Taysha Gene Therapies, Inc.
DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha’s AAV-based Gene Therapy Programs
October 24, 2022 19:30 ET
|
Taysha Gene Therapies, Inc.
- Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; new collaboration aimed at enhancing development of two of Taysha’s novel product candidates for rare monogenic...
Taysha Gene Therapies Announces Presentations at the Upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT)
October 06, 2022 07:00 ET
|
Taysha Gene Therapies, Inc.
DALLAS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...